Drug intelligence / Profile preview

Mobilia

Development stage: Unknown
Lead developer: JW Theriac Pharmaceutical
Modality: Small Molecules
Administration: Subcutaneous

Overview

**Mobilia** is a small-molecule CXCR4 antagonist developed by JW Theriac Pharmaceuticals for hematopoietic stem cell mobilization in patients with cancer. It contains **plerixafor** as the active ingredient at 20 mg/mL and is approved for mobilizing hematopoietic stem cells into peripheral blood for subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The product is administered by **subcutaneous injection** approximately 11 hours before initiation of stem cell collection and is supplied as a clear, colorless to pale yellow solution in vials.

Brand names: Mobilia
Other names: plerixafor

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on Mobilia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mobilia.

Explore the full profile